SLC5A2 and Iron deficiency anemia: Consistent with this hypothesis of greater use of iron after SGLT2 inhibition, treatment with dapagliflozin led to a higher incidence of iron deficiency during 12 months, defined using ferritin and TSAT criteria, compared with treatment with placebo.